natgillin/translations-raw huggingface dataset:
Data for patienter med kreatininclearance &lt; 30 ml/min er begrænsede, og der er ingen data for dialysepatienter.
Data in patients with creatinine clearance &lt; 30 mL/min are limited and there are no data for patients on dialysis.
Data for patienter med svært nedsat nyrefunktion (kreatininclearance &lt; 30 ml/min) er begrænsede, og der er ingen data for dialysepatienter.
Data in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) are limited and there are no data for patients on dialysis.
20 m til 52 m [ &lt; 0,0001]
20 to 52 [ &lt; 0.0001]
Data for patienter med svært nedsat nyrefunktion (kreatininclearance &lt; 30 ml/min) er begrænsede, og der er ingen data for patienter, som er i dialyse.
Data in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) are limited and there are no data for patients on dialysis, therefore riociguat is not recommended in these patients.
- dine nyrer ikke fungerer korrekt (kreatininclearance &lt; 30 ml/min), eller hvis du er i dialyse, da anvendelsen af dette lægemiddel ikke anbefales - du har moderate leverproblemer (nedsat leverfunktion, Child Pugh B) - du starter eller stopper med at ryge under behandlingen med dette lægemiddel, da dette kan påvirke niveauet af riociguat i dit blod.
your kidneys do not work properly (creatinine clearance &lt; 30 ml/min) or if you are on dialysis as the use of this medicine is not recommended.
-781,5 til -82,1 [ &lt; 0,0001] Ændring i WHO-funktionsklasse Riociguat IDT (n=254)
-781.5 to -82.1 [ &lt; 0.0001]
Estimeret hyppighed: Meget almindelig (≥1/10), almindelig (≥1/100 til &lt; 1/10), ikke almindelig (≥1/1.000 til &lt; 1/100), sjælden (≥1/10.000 til &lt; 1/1.000), meget sjælden ( &lt; 1/10.000).
Frequency estimate: Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Kun en lille del af de inkluderede patienter i de vigtigste kliniske studier led af moderate til svære depressioner (basislinie HAM-D &gt; 25).
Only a small proportion of patients included in pivotal clinical trials had severe depression (baseline HAM-D &gt; 25).
I løbet af den 52 uger lange placebo-kontrollerede dobbeltblinde behandlingsperiode oplevede 14,4 % af de duloxetin-behandlede patienter og 33,1 % af de placebo- behandlede patienter en tilbagevenden af deres depressive symptomer (p &lt; 0,001).
During the 52-week placebocontrolled double blind treatment phase 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p &lt; 0.001).
Forhøjede plasmakoncentrationer af duloxetin forekommer hos patienter med svært nedsat nyrefunktion i hæmodialyse (kreatininclearance &lt; 30 ml/min).
Increased plasma concentrations of duloxetine occur in patients with severe renal impairment on haemodialysis (creatinine clearance &lt; 30 ml/min).
Effekten af duloxetin 30-120 mg (fleksibel dosering) en gang dagligt hos ældre patienter ( &gt; 65 år) med generaliseret angst blev evalueret i et studie, som viste statistisk signifikant forbedring i HAM-A totalscoren hos duloxetinbehandlede patienter sammenlignet med placebobehandlede patienter.
The efficacy of duloxetine 30-120 mg (flexible dosing) once a day in elderly patients ( &gt; 65 years) with generalised anxiety disorder was evaluated in a study that demonstrated statistically significant improvement in the HAM-A total score for duloxetine treated patients compared to placebo treated patients.
Duloxetin 60 mg til 120 mg en gang daglig viste statistisk signifikant fordel sammenlignet med placebo (p &lt; 0.0001) ved forebyggelse af tilbagefald målt som tid til tilbagefald.
Duloxetine 60 mg to 120 mg once daily demonstrated statistically significant superiority compared to placebo (p &lt; 0.001) on the prevention of relapse, as measured by time to relapse.
Duloxetine Zentiva må ikke bruges til patienter med svært nedsat nyrefunktion (kreatininclearance &lt; 30 ml/min, se pkt.
Duloxetine Zentiva must not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min; see section 4.3).
INFEKTIONER FÃ¸r behandling med Zessly
INFECTIONS Before treatment with Zessly
** PASI 75 respons for studie 10 ikke inkluderet som følge af lav N; p &lt; 0.001 for infliximab vs. placebo i uge 24 for studie 11.
** PASI 75 response for study 10 not included due to low N; p &lt; 0.001 for infliximab vs. placebo at week 24 for study 11.
Infliximab hÃ¦mmer den funktionelle aktivitet af TNFÎ± i en lang rÃ¦kke forskellige in vitro bioassays.
Infliximab inhibits the functional activity of TNFÎ± in a wide variety of in vitro bioassays.
(≥ 1/100 til &lt; 1/10); ikke almindelig (≥ 1/1.000 til &lt; 1/100); sjælden (≥ 1/10.000 til &lt; 1/1.000); meget sjælden ( &lt; 1/10.000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Infliximab krydsreagerer ikke med TNFÎ± fra andre arter end mennesker og chimpanser.
Infliximab does not cross react with TNFÎ± from species other than human and chimpanzee.
I uge 16 blev 47 placebopatienter med &lt; 10 % forbedring fra udgangspunktet i både hævede og ømme led flyttet til infliximab-induktion (tidlig overflytning).
At week 16, 47 placebo patients with &lt; 10% improvement from baseline in both swollen and tender joint counts were switched to infliximab induction (early escape).
Infliximab er et monoklonalt antistof - en type protein, der binder sig til et specifikt mÃ¥l i kroppen kaldet TNF (tumornekrosefaktor) alfa.
Infliximab is a monoclonal antibody - a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha.
Infliximab blev undersÃ¸gt i et klinisk studie med 120 patienter (alder: 4-17 Ã¥r) med aktiv juvenil reumatoid arthrithis til trods for behandling med methotrexat.
Infliximab was studied in a clinical study in 120 patients (age range: 4-17 years old) with active juvenile rheumatoid arthritis despite methotrexate.
b Baseret på patienter med PASI &gt; 2.5 ved baseline for studie 10, og patienter med &gt; 3 % BSA psoriasis hud påvirkning ved baseline af studie 11.
b Based on patients with PASI ≥ 2.5 at baseline for study 10, and patients with ≥ 3% BSA
Infliximab forbedrede livskvaliteten i studie 6 og studie 7, hvilket bekrÃ¦ftedes ved statistisk signifikant forbedring i bÃ¥de et sygdomsspecifikt mÃ¥l, IBDQ, og ved forbedring i den almindelige 36-punkt korte udgave af spÃ¸rgeskema SF-36.
In study 6 and study 7, infliximab improved quality of life, confirmed by statistically significant improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36-item short form survey SF-36.
b Alle infliximab doser er givet i kombination med methotrexat og folat samt eventuelt kortikosteroider og/eller NSAIDs c p &lt; 0,001, for hver infliximab-behandlingsgruppe versus kontrol d Større værdier indikerer mere uarbejdsdygtighed.
Mean ± SDc b all infliximab doses given in combination with methotrexate and folate with some on corticosteroids and/or NSAIDs c p &lt; 0.001, for each infliximab treatment group vs. control d greater values indicate more joint damage.
Infliximab er et kimerisk human-murin monoklonalt antistof, der binder sig med hÃ¸j affinitet til bÃ¥de oplÃ¸selige og transmembrane former af TNFÎ±, men ikke til lymphotoxin Î± (TNFÎ²).
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFÎ± but not to lymphotoxin Î± (TNFÃ).
I studie 12 hos patienter med plaque psoriasis var andelen af patienter, der opnåede PASI 75 i uge 10 71,7 % i 3 mg/kg infliximab-gruppen, 87,9 % i 5 mg/kg infliximab-gruppen og 5,9 % i placebogruppen (p &lt; 0,001).
In study 12 in patients with plaque psoriasis, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group (p &lt; 0.001).
Infunder ikke Zessly i den samme intravenÃ¸se slange med andre midler.
Do not infuse Zessly concomitantly in the same intravenous line with other agents.
Inden for systemorganklasserne er bivirkningerne opført under overskrifter for hyppighed ved brug af følgende kategorier: meget almindelig (≥ 1/10); almindelig
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000
infliximabvedligeholdelse 5 mg/kg (n = 113) (p-vÃ¦rdi)
infliximab Maintenance 5 mg/kg (n = 113) (p value)
Slimhindeheling i uge 30a a p &lt; 0,001, for hver infliximab-behandlingsgruppe mod placebo.
Mucosal healing at week 30a a p &lt; 0.001, for each infliximab treatment group vs. placebo.
Infliximabs sikkerhed og virkning hos bÃ¸rn og unge under 18 Ã¥r for indikationerne juvenil idiopatisk arthritis, psoriasis arthritis og ankyloserende spondylitis er ikke klarlagt.
The safety and efficacy of infliximab in children and adolescents younger than 18 years for the indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been established.
Debuterende eller forværring af allerede eksisterende psoriasis, inklusive pustuløs psoriasis (primært palmoplantaris), urticaria, udslæt, pruritus, øget svedtendens, tør hud, svampedermatitis, eksem, alopeci.
New onset or worsening psoriasis including pustular psoriasis (primarily palm &amp; soles), urticaria, rash, pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.
Infliximabs sikkerhed og virkning blev vurderet i et multicenter, randomiseret, open-label, parallelgruppe klinisk studie 15 hos 60 pÃ¦diatriske patienter i alderen 6 til 17 Ã¥r (medianalder 14,5 Ã¥r) med moderat til svÃ¦r aktiv colitis ulcerosa (Mayo-score pÃ¥ 6-12; endoskopisk subscore â¥ 2) med utilstrÃ¦kkelig respons pÃ¥ konventionel behandling.
The safety and efficacy of infliximab were assessed in a multicenter, randomised, open-label, parallel-group clinical study 15 in 60 paediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; endoscopic subscore ≥ 2) with an inadequate response to conventional therapies.
En større andel patienter i den kombinerede infliximab-behandlingsgruppe var i stand til at afbryde kortikosteroider og stadig blive i klinisk remission sammenlignet med placebobehandlingsgruppen i både uge 30 (22,3 % mod 7,2 %, p &lt; 0,001, samlede studie 6 og studie 7 data) og uge 54 (21,0 % mod 8,9 %, p = 0,022, studie 6 data).
A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs. 7.2%, p &lt; 0.001, pooled study 6 &amp; study 7 data) and week 54 (21.0% vs. 8.9%, p = 0.022, study 6 data).
a p &lt; 0,001, for hver infliximab-behandlingsgruppe versus kontrol.
a p &lt; 0.001, for each infliximab treatment group vs. control.
(p &lt; 0,001)* * P-værdier repræsenterer hver infliximab-behandlingsgruppe vs. AZA monoterapi.
* P-values represent each infliximab treatment group vs. AZA monotherapy.
Infliximabs sikkerhed og virkning hos bÃ¸rn under 6 Ã¥r med Crohns sygdom er ikke klarlagt.
The safety and efficacy of infliximab have not been studied in children with Crohn's disease below the age of 6 years.
Infliximab med eller uden AZA blev vurderet i et randomiseret, dobbeltblind studie med aktiv komparator hos 508 voksne patienter med moderat til svÃ¦r Crohns sygdom (CDAI â¥ 220 â¤ 450).
Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study of 508 adult patients with moderate to severe Crohn's disease (CDAI â¥ 220 â¤ 450) who were naive to biologics and immunosuppressants and had a median disease duration of 2.3 years.
Infliximabs sikkerhed og virkning hos bÃ¸rn under 6 Ã¥r med colitis ulcerosa er ikke klarlagt.
The safety and efficacy of infliximab have not been studied in children with ulcerative colitis below the age of 6 years.
Infliximabs effekt og sikkerhed blev undersÃ¸gt i to multicenter, dobbelblind, placebokontrollerede studier hos 8 og 9, hos patienter med aktiv ankyloserende spondylitis (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score â¥ 4 og spinalsmerte â¥ 4 pÃ¥ en skala pÃ¥ 1-10).
Efficacy and safety of infliximab were assessed in two multicenter, double-blind, placebocontrolled studies 8 and 9 in patients with active ankylosing spondylitis (Bath Ankylosing
Median Forbedring fra baseline i HAQ gennemsnitligt over tid fra uge 30 til uge 54c Gennemsnit ± SDd a p &lt; 0,001, for hver infliximab-behandlingsgruppe mod kontrol.
Improvement from baseline in HAQ averaged over time from week 30 to week 54c
Under 1 måned 1 til &lt; 6 måneder 6 til &lt; 12 måneder 12 til &lt; 24 måneder 2 til &lt; 6 år 6 til &lt; 17 år
Under 1 month 1 to &lt; 6 months 6 to &lt; 12 months 12 to &lt; 24 months 2 to &lt; 6 years 6 to &lt; 17 years
Data for behandling i &gt; 24 timer er ikke tilgængelige.
Data on treatment for &gt; 24 hours is not available.
Bivirkningerne er opstillet efter hyppighed, de hyppigste først, efter følgende konvention: meget almindelig (≥1/10), almindelig (≥1/100 til &lt; 1/10), ikke almindelig (≥1/1.000 til &lt; 1/100), sjælden (≥1/10.000 til &lt; 1/1.000), meget sjælden ( &lt; 1/10.000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Børn &gt; 1 måned postnatalt, fortrinsvis post-operativt, er blevet vurderet ved behandling i op til 24 timer på intensivafdeling og udviste samme sikkerhedsprofil som voksne.
Children &gt; 1 month post-natal, predominantly post-operative, have been evaluated for treatment up to 24 hours in the ICU and demonstrated a similar safety profile as in adults.
Infusionshastighedens for vedligeholdelsesdosen skal tilpasses for at opnÃ¥ det Ã¸nskede sedationsniveau.
The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation.
Dexmedetomidins farmakokinetik hos personer med alvorligt nedsat nyrefunktion (kreatininclearance &lt; 30 ml/min) er uændret i relation til raske personer.
The pharmacokinetics of dexmedetomidine in subjects with severe renal impairment (creatinine clearance &lt; 30 ml/min) is not altered relative to healthy subjects.
Der er meget begrænsede data vedrørende virkning for patienter med en puls på &lt; 60, og der skal især udvises forsigtighed hos disse patienter.
Data on the effects of Dexdor in patients with heart rate &lt; 60 are very limited and particular care should be taken with such patients.
Data fra nyfødte (gestationsalder 28-44 uger) er meget begrænsede og er begrænset til vedligeholdelsesdoser &lt; 0,2 mikrogram/kg/t.
Data in new-born infants (28 - 44 weeks gestation) is very limited and restricted to maintenance doses ≤ 0.2 mcg/kg/h.
InfusionsvÃ¦sken skal rystes let for at blive blandet godt.
The solution should be shaken gently to mix well.
De estimerede farmakokinetiske parametre er: t½ cirka 1,5 timer, Vss cirka 93 liter og Cl cirka 43 l/time.
Plasma pharmacokinetics of dexmedetomidine is similar in the ICU population following infusion &gt; 24 h. The estimated pharmacokinetic parameters are: t1/2 approximately 1.5 hours, Vss approximately 93 litres and Cl approximately 43 l/h.
Frekvenskategorierne er defineret som følger: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til &lt; 1/10), ikke almindelig (≥ 1/1.000 til &lt; 1/100), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Frequency categories are defined as follows: Very common (≥ 1/10); Common (≥ 1/100 to &lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Not known (cannot be
* Arter mod hvilke aktivitet er påvist i kliniske studier Arter med naturlig middelfølsomhed Arter med &gt; 50 % erhvervet resistens i én eller flere medlemsstater ^ Alle methicillinresistente staphylococci bør betragtes som værende resistente over for doripenem
* species against which activity has been demonstrated in clinical studies species that show natural intermediate susceptibility species with &gt; 50% acquired resistance in one or more Member State ^ all methicillin-resistant staphylococci should be regarded as resistant to doripenem
11 % havde en APACHE II-score på &gt; 10, 9,5 % havde postoperative infektioner, 27 % havde en enkelt eller flere intraabdominale abscesser, og 4 % havde samtidig bakteriæmi ved baseline.
Eleven percent had an APACHE II score of &gt; 10, 9.5% had post-operative infections, 27% had single or multiple intra-abdominal abscesses and 4% had concurrent bacteraemia at baseline.
* 1 g hver 8. time som 4 timers infusion kan overvejes hos patienter med forhøjet renal clearance (især patienter med kreatininclearance (CrCl) &gt; 150 ml/min) og/eller ved infektioner, der skyldes non-fermenterende gramnegative patogener (såsom Pseudomonas spp.
* 1 g every 8 hours as a 4-hour infusion may be considered in patients with augmented renal clearance (particularly those with creatinine clearance (CrCl) ≥ 150 ml/min) and/or in infections due to non-fermenting gram-negative pathogens (such as Pseudomonas spp.
Af disse havde 50 % sent opstået respiratorassocieret pneumoni (defineret som opstået efter 5 dages mekanisk ventilation), 54 % havde en APACHE (akut fysiologisk og kronisk helbredsevaluering) II-score på &gt; 15, og 32 % fik samtidig aminoglykosider (76 % i mere end 3 dage).
Of these, 50% had late-onset VAP (defined as that occurring after five days of mechanical ventilation), 54% had an APACHE (Acute Physiology And Chronic Health Evaluation) II score &gt; 15 and 32% received concomitant aminoglycosides (76% for more than 3 days).
S  1 mg/l og R &gt; 1 mg/l
S  1 mg/l and R &gt; 4 mg/l
Ligesom for andre betalaktamantibiotika er det påvist, at den tid, hvori doripenems plasmakoncentration overskrider infektionsorganismens mindste hæmmende koncentration (%T &gt; MIC), bedst korrelerer med effekten i prækliniske farmakokinetiske/farmakodynamiske (PK/PD) studier.
Similar to other beta-lactam antimicrobial agents, the time that the plasma concentration of doripenem exceeds the minimum inhibitory concentration (%T &gt; MIC) of the infecting organism has been shown to best correlate with efficacy in pre-clinical pharmacokinetic/pharmacodynamic (PK/PD) studies.
Hvis infusionstiden for doripenem forlænges til 4 timer, maksimeres %T &gt; MIC for en given dosis, og dette danner grundlaget for muligheden for at give infusioner med en varighed på 4 timer til patienter med nosokomiel pneumoni herunder respiratorassocieret pneumoni.
Extending the infusion time of doripenem to 4 hours maximises the % T &gt; MIC for a given dose and is the basis for the option to administer 4-hour infusions in patients with nosocomial pneumonia including ventilator-associated pneumonia.
For alle grader af nyrefunktion indikerer Monte Carlo-simuleringer med patogenfølsomhedsresultater fra afsluttede fase III-studier og farmakokinetiske populationsdata, at %T &gt; MIC-målet på 35 % blev nået hos mere end 90 % af patienterne med nosokomiel pneumoni, komplicerede urinvejsinfektioner og komplicerede intraabdominale infektioner.
Monte Carlo simulations using pathogen susceptibility results from completed phase III trials and population PK data indicated that the %T &gt; MIC target of 35% was achieved in greater than 90% of patients with nosocomial pneumonia, complicated urinary tract infections and complicated intra-abdominal infections, for all degrees of renal function.
Forsigtighed tilrådes ved valg af antibakterielt middel og dosis ved behandling af patienter med sen respiratorassocieret pneumoni ( &gt; 5 dages indlæggelse) og ved andre tilfælde af nosokomiel pneumoni, hvor der er mistanke om eller påvist patogener med nedsat følsomhed såsom Pseudomonas spp.
Caution on the choice of antibiotic agent and dose should be taken when treating patients with late-onset ventilator-associated pneumonia ( &gt; 5 days hospitalisation) and in other nosocomial pneumonia cases where pathogens with decreased susceptibility are suspected or confirmed, such as Pseudomonas spp.
En infusion af 4 timers varighed kan være mere hensigtsmæssig til alvorligt syge patienter eller patienter med svækket immunforsvar, når MIC for doripenem over for de(t) kendte eller mistænkte patogen(er) er bestemt til eller forventes at være &gt; 0,5 mg/l for at nå målet på 50 % T &gt; MIC hos mindst 95 % af patienterne (se pkt.
In seriously ill patients or those with an impaired immune response, a 4-hour infusion time may be more suitable when the MIC of doripenem for the known or suspected pathogen(s) has been shown or is expected to be &gt; 0.5 mg/l, in order to reach a target attainment of 50% T &gt; MIC in at least 95% of the patients (see section 4.2).
Der er ikke fastsat doseringsrekommandationer for patogener med MIC &gt; 1 mg/l ved kontinuerlig renal substitutionsterapi på grund af potentiel akkumulering af doripenem og dets metabolit doripenem-M-1 (se pkt.
Dosing recommendations for pathogens with MIC &gt; 1 mg/l have not been established for continuous renal replacement therapy due to the potential for accumulation of doripenem and doripenem-M-1 metabolite (see sections 4.4 and 5.2).
Efter en enkelt dosis på 500 mg Doribax steg AUC for doripenem 1,6-gange, 2,8-gange og 5,1-gange hos forsøgspersoner med henholdsvis let (CrCl 51-79 ml/min), moderat (CrCl 31-50 ml/min) og svært (CrCl  30 ml/min) nedsat nyrefunktion sammenlignet med raske forsøgspersoner i samme aldersgruppe med normal nyrefunktion (CrCl &gt; 80 ml/min).
Following a single 500 mg dose of Doribax, doripenem AUC increased 1.6-fold, 2.8-fold, and 5.1-fold in subjects with mild (CrCl 51-79 ml/min), moderate (CrCl 31-50 ml/min), and severe renal impairment (CrCl  30 ml/min), respectively, compared to age-matched healthy subjects with normal renal function (CrCl &gt; 80 ml/min).
Til patienter med svært nedsat nyrefunktion (CrCl &lt; 30 ml/min) gives 250 mg doripenem hver 12. time (se pkt.
In patients with severe renal impairment (CrCl &lt; 30 ml/min), the dose of doripenem should be 250 mg every 12 hours (see section 6.6).
Ud fra især farmakokinetiske og farmakodynamiske overvejelser vil en infusionstid på 4 timer muligvis være bedst for at øge den procentdel af doseringsintervallet, hvor doripenems plasmakoncentration overstiger den mindste hæmmende koncentration (%T &gt; MIC) (se pkt.
Based mainly on PK/PD considerations, a 4-hour infusion time may be more suitable to maximize the percentage time during the dosing interval that the plasma concentration of doripenem exceeds the minimum inhibitory concentration (%T &gt; MIC), (see section 5.1).
Infunder den resterende del af oplÃ¸sningen, sÃ¥ledes at der indgives en dosis pÃ¥ 250 mg doripenem.
Infuse all of the remaining solution to administer a 250 mg dose of doripenem.
Dosisjustering er ikke nødvendig til patienter med let nedsat nyrefunktion (dvs. kreatininclearance (CrCl) &gt; 50 til  80 ml/min).
In patients with mild renal impairment (i.e. creatinine clearance (CrCl) is &gt; 50 to  80 ml/min), no dose adjustment is necessary.
Infunder hele denne oplÃ¸sning, sÃ¥ledes at der indgives en dosis pÃ¥ 500 mg doripenem.
Infuse all of this solution to administer a 500 mg dose of doripenem.
Infunder hele denne oplÃ¸sning, sÃ¥ledes at der indgives en dosis pÃ¥ 250 mg doripenem.
Infuse all of this solution to administer a 250 mg dose of doripenem.